Navigation Links
Grifols Starts Construction of a New Plasma Fractionation Plant in Barcelona (Parets Del Valles)
Date:2/18/2011

BARCELONA, Spain, Feb. 18, 2011 /PRNewswire/ -- Grifols, the Spanish group which specializes in the hospital-pharmaceutical sector and is one of the world's leading producers of plasma products, will shortly start construction of a new plant representing an investment of 20 million euros that will employ about 100 people, as soon as it obtains local permits and licenses. The new facilities will have the capacity to fractionate 1 million liters of plasma a year (with potential to expand to 2 million), allowing the group to double its existing fractionation capacity in Spain. The Grifols plant in Los Angeles, California, currently has a capacity of 2.2 million liters, giving the group total capacity of 6.3 million liters in 2014.

The construction work is scheduled to take 18 months, after which the process of obtaining licenses from the FDA (Food & Drug Administration) in the United States and from the EMA (European Medicines Agency) will begin. This is expected to take no more than two years, as the new plant will fractionate plasma through to the intermediate product stage. The purification, inactivation and sterile filling stages for the different proteins will be performed at Grifols' existing facilities at Parets del Valles, which have already been adapted to absorb this increased level of production.

The new plant will use the very latest technology and will make maximum use of automation. Grifols Engineering S.A., a group company which specializes in the engineering of biotechnological and pharmaceutical processes, has designed the new facilities and will manage the construction project. The plant will also serve as a model for the future construction of another fractionation plant in the United States (San Marcos, Texas) due to start in 2014, and delivering a maximum capacity of 4 million liters.

The new plant forms part of the 433 million euro investment plan for the period 2008-2012, approved at the end of 2007 by the Board of Directors. Key features of this investment plan, which is running to schedule, include the new intravenous immunoglobulin (IVIG) production plant in Los Angeles, completed in 2010 and now at the validation stage, together with the new plasma testing laboratory in San Marcos, Texas, also completed in 2010 and at the validation stage.

This means that Grifols has completed over 90% of the projects included in the investment plan for the period, projects which are designed to underpin the company's growth plans for the period 2014-2018/2020.  

About Grifols

Grifols is a Spanish holding company, specializing in the hospital-pharmaceutical sector, and with a presence in over 90 countries. Since May 2006 it has been listed on the Spanish Continuous Market, and it is included in the Ibex-35. Grifols is the leading European plasma products company, and the fourth-largest producer in the world. The company plans to strengthen its position within the industry as a vertically integrated company, on the basis of its ongoing investment program. In terms of raw material, Grifols has secure plasma supplies from its network of 80 plasmapheresis centers in the United States, while its production plants in Barcelona (Spain) and Los Angeles (United States) ensure that it has the fractionation capacity to satisfy rising demand. In addition, the company has implemented an ambitious investment plan to enable it to deliver sustained growth over the next 8 to 10 years.


'/>"/>
SOURCE Grifols
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Health Robotics CytoCare(TM) Global Expansion Continues With Grifols International in Latin America
2. AMDL Diagnostics, Inc. Enters Into Exclusive Distribution Agreement With Grifols USA, LLC to Advance Commercialization of DR-70 Onko-Sure(TM) Cancer Test
3. Grifols Agrees to Acquire Intellectual Property for Treatment of Post-Polio Syndrome From Pharmalink AB
4. Health Robotics CytoCare Continues European Expansion With Grifols and Vall dHebron University Hospital
5. NASDAQ Removes TLCR From Biotechnology Index Pending FTC Decision on Grifols Acquisition
6. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
7. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
8. Impliant Restarts Pivotal Clinical Trial for Patented TOPS(TM) Spine System
9. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
10. U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)
11. Presbyterian Hospital Dallas Starts Advanced Breast-Cancer Risk-Assessment Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... LONDON , April 19, 2017 ... to stimulate an immune response in pets such ... vaccine products are of various types such as ... Vaccines, Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. ... such as virus or bacteria, which have been ...
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global ... and Gynecology markets with innovative and proprietary products, will ... 31, 2017 after the market close on Tuesday, May ... a conference call and webcast to discuss its financial ... at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). ...
(Date:4/18/2017)...  Socionext Inc. and SOINN Inc. today announced ... which Socionext extracts and delivers biometrics data to ... results in reading ultrasound images from Socionext,s viewphii™ ... results will be introduced at Medtec Japan, held ... 4505 & 4507. In this initial ...
Breaking Medicine Technology:
(Date:4/23/2017)... ... 23, 2017 , ... Altura Communication Solutions, a nationwide provider ... certification and SMB specialization. Altura is now qualified to sell, install and ... Select Certification, Altura fulfilled the training and exam requirements for the Cisco Small ...
(Date:4/22/2017)... (PRWEB) , ... April 22, 2017 , ... ... to his role as Vice President of Sales and Business Development at OAKWORKS, ... GPO/IDN business partner engagements, business development, and strategic planning for the company. ...
(Date:4/21/2017)... ... ... staff at Palm Beach Face is proud to announce that their practice founder, Michael ... take place on April 23rd, the London Marathon has a long tradition of raising funds ... team EMPOWER, raising money for the international charity, Smile Train. , Started in ...
(Date:4/21/2017)... ... ... Brady (NYSE:BRC), a global leader in industrial and safety printing systems ... label materials received certification for the BS5609 British Marine Standard. This internationally recognized standard ... use on chemical drums shipped by sea. , “Achieving BS5609 certification for ...
(Date:4/21/2017)... , ... April 21, 2017 , ... The Patient Advocacy ... Health System, with the 2017 Ruth Ravich Patient Advocacy Award in recognition ... advocates. DeVaro was honored with the award at The Beryl Institute’s annual Patient ...
Breaking Medicine News(10 mins):